MedTrace Logo

Financial Incentives for Low Socioeconomic Diabetic Patients

NCT03506230 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2018-12-17

No results posted yet for this study

Summary

Patients with uncontrolled diabetes \[glycated hemoglobin (Hba1c)\>8.5%\] from low socioeconomic status neighborhoods in Jerusalem will be recruited. They will be randomly assigned to an intervention group and a control group. The intervention group will be offered a bonus to buy their medications, 100 Israeli Shekels (ILS) (30$) each month for 3 months, if they reduce their HBA1c by 0.7% or if their HbA1c level reaches 7.5%. After 6 months they will be eligible for another bonus for one month if they improve their HbA1c by 0.3% from the previous test. The control group will buy medications as usual. All participants will be contacted by phone and will be encouraged to contact their doctor, to perform blood tests and to maintain a healthy lifestyle.

Conditions

  • Type2 Diabetes Mellitus

Interventions

BEHAVIORAL

Incentives

A bonus to buy their medications if they reduce their HBA1c

Sponsors & Collaborators

  • Clalit Health Services

    lead OTHER

Principal Investigators

  • Amnon Lahad, MD, MPH · Clalit Health Services

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-25
Primary Completion
2019-11-30
Completion
2019-12-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03506230 on ClinicalTrials.gov